On October 15, the United States Court of Appeals for the Federal Circuit (CAFC), in St. Jude Medical, LLC v. Snyders Heart Valve LLC, affirmed an inter partes review (IPR) decision of the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (the Board) rejecting St. Jude Medical, LLC’s (St. Jude) contention that Snyders Heart Valve LLC’s (Snyders) artificial heart valve patent was invalid. The CAFC also reviewed a second IPR decision, wherein it reversed the Board’s decision that certain claims of the patent were invalid and affirmed the Board’s decision that the remaining claims were valid.
Litigation
- CAFC Affirms Merck’s Win at PTAB over Mylan Challenge to Diabetes Treatment Claims
- Federal Circuit Clarifies Alice Step Two Analysis in Reversal of District Court’s Rule 12 Dismissal
- Jump Rope Company Asks High Court to Weigh in on CAFC Approach to Collateral Estoppel for PTAB Invalidations
- Review Not Warranted: SG Tells SCOTUS to Scrap Amgen’s Case on Enablement Test for Biotech Patents
- Novartis to Appeal CAFC’s ‘Unprecedented’ U-Turn in Ruling on Multiple Sclerosis Drug Claims to SCOTUS
Recent Posts
- CAFC Affirms Merck’s Win at PTAB over Mylan Challenge to Diabetes Treatment Claims
- Federal Circuit Clarifies Alice Step Two Analysis in Reversal of District Court’s Rule 12 Dismissal
- The Judicial Balancing Act: How Judges Manage Competing Interests in Trade Secret Cases
- Jump Rope Company Asks High Court to Weigh in on CAFC Approach to Collateral Estoppel for PTAB Invalidations
- Review Not Warranted: SG Tells SCOTUS to Scrap Amgen’s Case on Enablement Test for Biotech Patents